Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis

LONDON, NEW YORK and HAMILTON, Bermuda, April 30, 2010 – Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma"), the
global private equity firm focused on the biotechnology and pharmaceutical
industries, announced today the enrolment of the first patient into its Phase
III trial of TDT 067, terbinafine in Transfersomes(R), for the topical
treatment of onychomycosis (also known as a fungal [...]